Monopro (Latanoprost)

Latanoprost, the active ingredient in Monopro, is a prostaglandin analog presented as eye drops for ocular use. It treats elevated intraocular pressure, open-angle glaucoma and ocular hypertension in adults.

GNH USA supplies Monopro as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to lower intraocular pressure in several ocular conditions.

- Elevated intraocular pressure: reduces pressure to help prevent optic nerve damage. - Open-angle glaucoma: lowers pressure to slow disease progression and preserve visual field. - Ocular hypertension: decreases pressure to reduce risk of developing glaucoma.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness (hyperemia): mild to moderate conjunctival injection. - Increased eyelash growth (hypertrichosis): longer, thicker lashes. - Iris color change: gradual darkening of the iris. - Eye irritation or foreign body sensation. - Blurred vision: transient visual disturbance. - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, itching, or rash requiring medical attention. - Uveitis or ocular inflammation: pain, redness, and photophobia. - Macular edema: reduced central vision, especially in diabetic patients. - Vision loss: rare but serious, necessitating immediate evaluation.

When prescribing or using Latanoprost, consider the following precautions to ensure safe and effective therapy.

- Monitor intraocular pressure: measure regularly after initiation. - Assess for ocular irritation: report persistent redness or discomfort. - Avoid use in active intraocular inflammation: may exacerbate condition. - Caution in patients with known hypersensitivity to prostaglandin analogs. - Pregnancy and breastfeeding: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents; awareness of these interactions helps maintain therapeutic efficacy.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops: additive hyperemia and pigmentation. - Use with non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy. - Systemic carbonic anhydrase inhibitors: can diminish intraocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction may cause hypotony. - Corticosteroid eye drops: may counteract pressure‑lowering effect. - Contact lens wearers: may experience increased lens deposits or irritation.